|
Improvement of carcinoid syndrome (CS) symptoms and quality of life (QoL) in CS patients treated with somatostatin analogs (SSAs): Results from longitudinal patient surveys. |
|
|
Consulting or Advisory Role - Novartis; Oxigene |
Research Funding - Dicerna; Genentech/Roche; Ipsen (Inst); Novartis; Novartis (Inst) |
|
|
Research Funding - Novartis; Pfizer |
|
|
Consulting or Advisory Role - Functional Assessment of Chronic Illness Therapy; NorthShore University HealthSystem; Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
Research Funding - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
Stock and Other Ownership Interests - Zafgen |
Research Funding - AstraZeneca; Bayer; CSL Behring; GlaxoSmithKline; Janssen; Novartis; Pfizer |
|
|
Research Funding - AstraZeneca; Janssen; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
|
|
|
Stock and Other Ownership Interests - FACIT.org |
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; GlaxoSmithKline; Novartis; Pfizer; PledPharma; Puma Biotechnology |
Research Funding - Bayer (Inst); Genentech (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen |